72
Participants
Start Date
August 31, 2011
Primary Completion Date
August 31, 2014
Study Completion Date
January 31, 2016
Inotuzumab Ozogamicin
"Part 1: Administered intravenously as 2 - 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total dose per cycle 0.8 mg/m\^2 to 2.0 mg/m\^2.~Part 2 Expansion and Part 3 Phase 2: Administered intravenously as 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total initial dose per cycle 1.8 mg/m\^2."
Cleveland Clinic, Cleveland
Karmanos Cancer Institute, Detroit
Karmanos Cancer Institute at Farmington Hills, Farmington Hills
The University of Chicago Medical Center, Chicago
The University of Texas MD Anderson Cancer Center, Houston
Stanford Unversity Cancer Clinical Trials Office, Palo Alto
Stanford Unversity Hospital and Clinics, CTRU, Palo Alto
Stanford Cancer Institute, Stanford
Stanford University Hospital and Clinics, Stanford
Seattle Cancer Care Alliance, Seattle
City of Hope National Medical Center, Duarte
Massachusetts General Hospital (MGH), Boston
Brigham and Women's Hospital (BWH), Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Lead Sponsor
Collaborators (1)
UCB Pharma
INDUSTRY
Pfizer
INDUSTRY